Final late-stage Clavis drug fails in Phase III
This article was originally published in Scrip
Clavis Pharma's last great hope landed with a dull thud on 1 April when the Norwegian company said it is reviewing "strategic options" now that elacytarabine has failed to improve survival for patients with relapsed or refractory acute myeloid leukemia (AML) in the Phase III CLAVELA clinical trial.
You may also be interested in...
Aspen Neuroscience, Pandion and iTeos raised $70m, $80m and $125m, respectively. Also, Glide Healthcare closed a €416m ($450m) fund; ElevateBio, Kallyope and SutroVax reveal VC mega-rounds; and Dragonfly adds new funding to its partnering proceeds.
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
Clinical trials in a range of diseases continue to be impacted by concerns about patient safety and health care resources as the COVID-19 pandemic grows.